Therapeutic area
Cardiometabolic biotech companies
The 7 cardiometabolic companies we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.
Companies
| Company | Most advanced program | Cash & investments | Runway | Profile |
|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals | Amvuttra · ATTR amyloidosisApproved | $3.31B2026-06-30 | — | archived |
| IONSIonis Pharmaceuticals | Tryngolza · familial chylomicronemia syndromeApproved | $2.70B2026-06-30 | ~71 mo | archived |
| VKTXViking Therapeutics | VK2735 (subcutaneous) · Obesity / overweight with comorbiditiesPhase 3 | $502M2026-06-30 | ~13 mo | maintained |
| RAREUltragenyx Pharmaceutical | Crysvita · X-linked hypophosphatemiaApproved | $436M2026-06-30 | ~9 mo | archived |
| LQDALiquidia Corporation | YUTREPIA (treprostinil) inhalation powder · Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)Approved | $284M2026-06-30 | — | archived |
| AMGNAmgen | TEPEZZA · thyroid eye diseaseApproved | no filing parsed | — | archived |
| ARWRArrowhead Pharmaceuticals | Plozasiran · familial chylomicronemia syndromeApproved | no filing parsed | — | archived |
Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.
Upcoming trial milestones
- 2026-12 · IONS · Donidalorsen OLE: Donidalorsen in Hereditary angioedema prophylaxis — primary completion ClinicalTrials.gov
- 2027-08 · RARE · MCE study: Triheptanoin in Long-chain fatty acid oxidation disorders — primary completion ClinicalTrials.gov
- 2027-08-20 · ARWR · YOSEMITE: Zodasiran in Homozygous familial hypercholesterolemia — primary completion ClinicalTrials.gov
- 2027-09 · RARE · GTX-301: DTX301 in Late-onset OTC deficiency — primary completion ClinicalTrials.gov
- 2027-12-27 · ALNY · TRITON-PN: Nucresiran in Hereditary ATTR amyloidosis with polyneuropathy — primary completion ClinicalTrials.gov
- 2028-07 · ARWR · SHASTA-10: Plozasiran in Hypertriglyceridemia (open-label extension) — primary completion ClinicalTrials.gov
- 2029-01-04 · AMGN · DeLLphi-312: Tarlatamab in Untreated extensive-stage small-cell lung cancer — primary completion ClinicalTrials.gov
- 2029-01-31 · AMGN · Etelcalcetide paediatric: Etelcalcetide in Secondary hyperparathyroidism on haemodialysis — primary completion ClinicalTrials.gov
- 2029-03 · ARWR · SHASTA-5: Plozasiran in Severe hypertriglyceridemia at high risk of acute pancreatitis — primary completion ClinicalTrials.gov
- 2029-06 · IONS · Donidalorsen paediatric: Donidalorsen in Hereditary angioedema, ages 2 to <12 — primary completion ClinicalTrials.gov
- 2030-05-28 · ALNY · TRITON-CM: Nucresiran in ATTR amyloidosis with cardiomyopathy — primary completion ClinicalTrials.gov
- 2030-08 · IONS · Olezarsen paediatric FCS: Olezarsen in Familial chylomicronemia syndrome — primary completion ClinicalTrials.gov
- 2030-09-30 · ALNY · ZENITH: Zilebesiran in Hypertension with high cardiovascular risk — primary completion ClinicalTrials.gov
A registry milestone is the date data collection is scheduled to end, not the date results are released.
FDA decisions
None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.
Educational information, not investment advice. See where each field comes from.